SMN2 and proximal spinal muscular atrophy: Unlike nusinersen, which targets the 10–27 region and uses methoxyethyl (MOE) modifications, this ASO utilized 2′-O-methyl (OME) modifications and was less effective in correcting SMN2 splicing in the mild Taiwanese SMA model, also causing an inflammatory response [59].